

---

## Contents

1	Introduction.....	3
1.1	Available treatment for PD.....	5
1.1.1	Medications.....	6
1.1.1.1	Levodopa.....	6
1.1.1.2	Dopamine agonists.....	6
1.1.1.3	MAO-B inhibitors.....	6
1.1.1.4	COMT inhibitors.....	6
1.1.1.5	Anticholinergics.....	7
1.1.1.6	Deep Brain Stimulation (DBS).....	7
1.1.1.7	Glutamate Antagonists.....	7
1.1.1.8	Antioxidants.....	7
1.2	Shortcoming and challenges of available treatment for PD.....	7
1.2.1	Symptomatic treatment.....	8
1.2.2	Side effects and long-term complications:.....	8
1.2.3	Surgical Interventions.....	8
1.2.4	Lack of Disease-Modifying Treatments.....	8
1.3	Lysosomal theory in PD.....	9
1.3.1	Alpha-Synuclein Accumulation.....	10
1.3.2	Genetic Mutations.....	10
1.3.3	Lysosomal Enzyme Dysfunction.....	10
1.3.4	Autophagy and Lysosomal Clearance.....	10
1.4	Significance of targeting endoplasmic reticulum for GCase in PD.....	15
1.5	Chaperone-based treatment strategies in PD: Importance and implications	17
2	Introduction.....	23
2.1	Material and method.....	27
2.1.1	Material.....	27
2.2	Methods.....	27
2.2.1	Determination of the pH-dependent rGCase activity profiles.....	27
2.2.2	Construction of rGCase homology models and their validation.....	28
2.2.2.1	Sequence Retrieval.....	28
2.2.2.2	Homology modeling.....	28

---

2.2.3	<i>In silico</i> study .....	29
2.2.3.1	Protein and ligand preparation, and grid generation .....	29
2.2.3.2	Docking.....	29
2.2.3.3	MD simulation .....	29
2.2.4	<i>In vitro</i> studies .....	30
2.2.4.1	Determination of rGCCase activity profiles in the presence of chaperone.. .....	30
2.2.4.2	pH-dependent residual activity assay.....	30
2.2.4.3	pH-dependent enzyme kinetics assay .....	31
2.2.4.4	<i>In vitro</i> thermal denaturation assay.....	32
2.2.5	Data analysis .....	32
2.3	Result and discussion .....	33
2.3.1	Determination of the pH-dependent rGCCase activity profiles.....	33
2.3.2	Construction of rGCCase homology models and their validation .....	34
2.3.3	<i>In silico</i> studies.....	39
2.3.3.1	Protein and ligand preparation, and grid generation .....	39
2.3.3.2	Docking.....	39
2.3.3.3	Molecular dynamics (MD) simulation.....	41
2.3.3.4	Root mean square deviation.....	42
2.3.3.5	Root mean square fluctuation (RMSF) and protein-ligand contact time.....	43
2.3.3.6	The radius of gyration ( $R_g$ ) and solvent accessible surface area (SASA).....	47
2.3.4	Determination of pH-dependent rGCCase enzyme activity profiles in the presence of chaperone .....	49
2.3.4.1	pH-dependent $IC_{50}$ measurement .....	49
2.3.4.2	pH-dependent residual activity assay.....	51
2.3.4.3	pH-dependent enzyme kinetics assay .....	53
2.3.4.4	Thermal denaturation assay (TDA) .....	55
2.4	Conclusion.....	56
2.5	Summary .....	58
3	Introduction .....	63
3.1	Material and method.....	66
3.1.1	Reagents .....	66
3.1.2	Homology modeling and validation.....	66
3.1.3	<i>In silico</i> study .....	67

---

3.1.3.1	High-throughput virtual screening based on pharmacophore, PAINS, molecular, and ADMET property filters.....	67
3.1.3.2	Virtual molecular docking.....	67
3.1.3.3	Molecular dynamics (MD) simulation .....	67
3.1.4	<i>In vitro</i> pH-dependent enzyme mechanistic study.....	68
3.1.4.1	Estimation of IC <sub>50</sub> .....	68
3.1.4.2	Evaluation of test compounds chaperoning property .....	68
3.1.4.3	Binding mode Study .....	69
3.1.4.4	Enzyme kinetics.....	69
3.1.5	Cell line studies.....	70
3.1.5.1	Neurotoxicity assay .....	70
3.1.5.2	Evaluation of test compounds on 6-OHDA-induced PD cell line model.....	71
3.1.5.3	Neurorestorative activity assay.....	71
3.1.5.4	GCase activity assay.....	71
3.1.5.5	Measurement of Reactive oxygen species (ROS) level .....	72
3.1.5.6	Measurement of protein-ligand interaction stability .....	72
3.2	Data and statistical analysis .....	73
3.3	Result and discussion.....	73
3.3.1	Homology modeling and validation .....	73
3.3.2	High-throughput virtual screening based on pharmacophores, PAINS, molecular and ADMET property filter .....	74
3.3.3	<i>In silico</i> study.....	78
3.3.3.1	Virtual molecular docking.....	78
3.3.3.2	Molecular dynamics (MD) simulation .....	82
3.3.3.2.1	RMSD .....	82
3.3.3.2.2	RMSF and PL-contacts time .....	84
3.3.3.2.3	Measurement of R <sub>g</sub> and SASA.....	91
3.3.4	<i>In vitro</i> pH-dependent enzyme study.....	93
3.3.4.1	Estimation of IC <sub>50</sub> .....	93
3.3.4.2	Evaluation of test compounds chaperoning property .....	94
3.3.4.3	Binding mode Study .....	96
3.3.4.4	Enzyme kinetics.....	96
3.3.5	Cell line study .....	98
3.3.5.1	Neurotoxicity assay .....	98

---

3.3.5.2	Evaluation of test compounds on 6-OHDA-induced cell line model	99
3.3.5.2.1	Neurorestorative activity assay	99
3.3.5.2.2	GCCase activity assay	102
3.3.5.2.3	Measurement of Reactive oxygen species (ROS) level	104
3.3.6	Measurement of protein-ligand interaction stability	105
3.4	Conclusion	107
3.5	Summary	108
4	Introduction	112
4.1	Materials and methods	113
4.1.1	Materials	113
4.1.2	Animals and their ethical statement	113
4.1.3	Experimental design for acute oral toxicity studies	114
4.1.4	Hematological analysis	116
4.1.5	Estimation of hepatic, renal and heart toxicity markers	117
4.1.6	Measurement of Organ coefficient	117
4.1.7	Histopathological examination	117
4.2	Statistical analysis	118
4.3	Results and discussion	118
4.3.1	Effect of GC466 on behavioural and physical changes in the acute oral toxicity study	118
4.3.2	Effect of GC466 on the body weight in the acute oral toxicity study	120
4.3.3	Effect of GC466 on the food and water intake in the acute oral toxicity Study	121
4.3.4	Effect of GC466 on the Haematological analysis in the acute oral toxicity study	123
4.3.5	Effect of GC466 on the organ coefficient in the acute oral toxicity study	124
4.3.6	Effect of GC466 on the serum biochemistry parameters in the acute oral toxicity study	126
4.3.7	Effect of GC466 on the microstructural (histological) changes of organ in the acute oral toxicity study	130
4.3.7.1	Effect of GC466 on the histological changes in liver in the acute oral toxicity study	131
4.3.7.2	Effect of GC466 on the histological changes in liver and lung in the acute oral toxicity study	132
4.3.7.3	Effect of GC466 on the histological changes in spleen in the acute oral toxicity study	134

---

4.3.7.4	Effect of GC466 on the histological changes in heart and brain in the acute oral toxicity study .....	136
4.4	Conclusion .....	138
4.5	Summary .....	139
5	Introduction.....	144
5.1	Materials and methods .....	147
5.1.1	Experimental animals and their ethical statement .....	147
5.1.2	Materials .....	147
5.1.3	Animal surgical operation for 6-OHDA administration .....	148
5.1.4	Experimental design .....	149
5.1.5	Neurobehavioral studies: .....	151
5.1.5.1	Rotational behaviour test.....	151
5.1.5.2	Grip Strength Test .....	151
5.1.5.3	Rotarod test.....	152
5.1.6	Measurement of striatal rat Dopamine level.....	152
5.1.7	Immunoblotting .....	153
5.1.8	Glucocerebrosidase (GCase) enzyme activity assay .....	154
5.1.9	Quantitative reverse transcription PCR (qRT-PCR).....	154
5.1.10	Assessment of nigral caspase 12 and caspase 3 activities .....	156
5.1.11	Nissl staining.....	156
5.1.12	Immunofluorescence.....	157
5.2	Statistical Analysis.....	158
5.2.1	Results.....	159
5.2.2	Neurobehavioral studies .....	159
5.2.2.1	Effect of GC466 on apomorphine-induced rotational behaviour in 6-OHDA-induced PD rats .....	159
5.2.2.2	Effect of GC466 on 6-OHDA-induced impairments in grip strength and motor coordination .....	160
5.2.3	Effect of GC466 on striatal rat Dopamine (DA) level.....	162
5.2.4	Effects of GC466 on 6-OHDA-induced alterations in nigral proteins (TH and pS129 $\alpha$ -syn expression).....	164
5.2.5	Effects of GC466 on 6-OHDA-induced alterations in nigral GCase activity.....	166
5.2.6	Effects of GC466 on 6-OHDA-induced alterations in nigral gene expression of ER stress markers (GRP78, CHOP, PARK, caspase 12, 9 and 3), TH and GCase .....	167

---

5.2.7	Effect of GC466 against 6-OHDA-induced alteration in nigral caspase-12 and caspase-3 activity.....	170
5.2.8	Effect of GC466 against 6-OHDA-induced DA neuronal loss in SNpc region.....	171
5.3	Discussion .....	175
5.4	Conclusion.....	179
5.5	Summary .....	179
6	Introduction .....	184
6.1	Materials and methods .....	185
6.1.1	Experimental Chemicals .....	185
6.1.2	Animals .....	185
6.1.3	Preparation of stock solution.....	186
6.1.4	Preparation of working solution.....	186
6.1.5	Preparation of calibration curve and quality control samples .....	186
6.1.6	Sample preparation or Extraction of GC466 compound.....	187
6.1.7	Method validation .....	187
6.1.7.1	Linearity and range .....	187
6.1.7.2	Precision and accuracy.....	188
6.1.7.3	Limit of detection (LOD) and limit of quantification (LOQ) .....	188
6.1.7.4	Stability .....	189
6.1.7.5	Recovery .....	189
6.1.8	Pharmacokinetic study in rats .....	189
6.1.9	Brain distribution and penetration ability study.....	190
6.1.10	Parameters of plasma pharmacokinetic, brain distribution, and brain penetration.....	191
6.2	Data analysis. ....	191
6.3	Results and Discussion.....	192
6.3.1	HPLC method development and validation .....	192
6.3.1.1	Assessment of selectivity, linearity, and range.....	193
6.3.1.2	Precision and accuracy determination .....	194
6.3.1.3	Determination of Limit of detection (LOD) and limit of quantification (LOQ)	194
6.3.1.4	Determination of stability .....	196
6.3.1.5	Determination of recovery .....	198
6.3.2	Plasma pharmacokinetic profile in rats .....	198

---

6.3.3	Brain penetration ability and tissue distribution study of GC466 in rats...	200
6.4	Conclusion .....	204
6.5	Summary .....	205
7	Summary .....	210
7.1	Scope for Further Work .....	212